Consequently, lorlatinib should be strongly recommended for initial treatment of advanced ALK+ NSCLC; however, its long-term CNS adverse effects and cardiovascular toxicity resulting from hyperlipidemia necessitate evaluation over an extended duration. This evidence concerns the gene ALK and hyperlipidemia.